ELECTREON
4.10.2021 17:51:08 CEST | Business Wire | Press release
ElectReon (TASE: ELWS.TA), the leading provider of wireless and in-road wireless electric vehicle (EV) charging technology, announced it has signed a 5-year agreement with Dan Bus Company, an Israeli bus company, to expand its wireless charging network to support public electric bus routes in Tel Aviv and the wider metropolitan area. The implementation, costing $9.4M USD, will supply 200 electric buses with active charging at operational city terminals (stations) for buses between bus trips and while passengers board and disembark.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005732/en/
This charging strategy will allow for the reduction of electrical grid connection capacities at the bus facilities and reduce vehicle battery capacity, size and weight for Dan Bus Company’s electric buses—curtailing fleet vehicle down-time and enabling extended operational hours. ElectReon will provide a full charging service at multiple operating terminals in the Tel Aviv Metropolitan Area and in Israel’s Southern District, for which Dan will pay a monthly fee for the complete charging service stack for approximately 200 electric buses. Dan elected to choose ElectReon’s Charging as a Service (CaaS) model, in which ElectReon finances the charging infrastructure at the terminals and provides operation services and maintenance throughout the length of the 5-year project. Additionally, the partners will explore the possibility of installing ElectReon’s wireless charging system for the rest of Dan's electric fleet and in Dan’s highway project 'Netivei Ayalon’.
In the first phase of the project, ElectReon will install its wireless charging system in 100 buses and at the major public transport terminal, Reading, in North Tel Aviv. As part of the second phase of the project that will take place within two years, the charging infrastructure will be expanded to other major terminals in Tel Aviv and in the south region of Israel, so that the company will provide wireless charging for about 200 buses in total.
“Not only will this be ElectReon’s first large-scale commercial project, it will also be a world-class showcase of wireless EV charging for fleet vehicles,” said Oren Ezer, CEO of ElectReon. “This will continue to demonstrate the improved efficiency and cost savings that electric bus fleet operators can expect by implementing wireless charging infrastructure.”
"In order to turn Dan's public transportation network in the Tel Aviv metropolitan area into a fully electric network, the company is currently establishing a charging infrastructure system and support for one of the largest public transportation operators in the region. We have tested ElectReon's technology and it has proven to be suitable for top-up charging at operational terminals as part of our day-to-day operations and workflows,” said Ofir Karni, CEO of Dan Bus Company, “This advanced technology is expected to enable our electric fleet to achieve greater range and extended operational hours while flattening peak energy consumption loads from overnight depot charging and simultaneously, allow us to maintain our essential maneuvering space and operational flexibility at our terminals. What is interesting that is out of an average 19 operational hours a day, one of our buses stands for about two hours in total at one of our terminals while drivers rest, switch over or wait to pick up passengers; according to our estimations, by just utilizing this time alone to charge the buses, we’re able to provide around 30% of the vehicle’s daily energy requirements.”
This agreement expands on the initial September 2020 collaboration between ElectReon and Dan Bus Company to deploy wireless EV charging infrastructure to actively charge a bus from a half mile of electrified wireless roadway between Tel Aviv University and the nearby train station as well as wireless stationary charging stations installed at the bus terminal at the beginning of the bus route. The bus operator was able to reduce the vehicle battery capacity by 90% by enabling the bus to actively charge while driving as well as increase vehicle operational hours due to the fact that less downtime for charging was required.
“We are proud to be expanding the ElectReon network in Tel Aviv significantly just a year after the initial pilot and our collaboration with Dan began,” said Ezer. “This momentum signals the growing need today for EV charging solutions across the global transportation market beyond the traditional charging station that enables a more seamless transition to electrification.”
Adding to the efficiency of the wireless charging infrastructure, the expanded agreement also includes ElectReon providing Dan Bus Company with a Charging as a Service (CaaS) financing model which will demonstrate the feasibility of the innovative financial model for the company and its customers globally.
About ElectReon
ElectReon is the leading provider of wireless charging solutions for electric vehicles (EVs), providing end-to-end charging infrastructure and services to meet the needs and efficiency demands of shared, public and commercial fleet operators and consumers. The company’s proprietary inductive technology dynamically (while in motion) and statically (while stopped) charges EVs quickly and safely, eliminating range anxiety, lowering total costs of EV ownership, and reducing battery capacity needs—making it one of the most environmentally sustainable, scalable, and compelling charging solutions available today. ElectReon works with cities and fleet operators on a charging as a service (CaaS) platform that enables cost-effective electrification of public, commercial, and autonomous fleets for smooth and continuous operation. For more information, visit electreon.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005732/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
